全球骨質疏鬆症市場及藥物分析:2010∼2015年

全球骨質疏鬆症市場及藥物分析:2010∼2015年 是由出版商Renub Research在2011年09月所出版的。 這份英文市場調查報告書包含72 Pages 價格從美金950起跳。

簡介

骨質疏鬆症是毫無徵兆，骨質慢慢減少的所謂「沈默的疾病」。全球骨質疏鬆症市場預計到2015年將達到160億美金。目前市場上既有以及開發中的治療法非常充實，因此預計今後此市場將大幅成長。

本報告提供全球骨質疏鬆症市場相關調查分析，4個藥物類別相關市場佔有率資料(2006∼2014年)，與9個藥物品牌相關的2007∼2015年銷售額與市場佔有率，彙整各地區趨勢，開發平台與未來發展預測，為您概述為以下內容。

第1章 摘要整理

第2章 全球骨質疏鬆症市場

第3章 全球骨質疏鬆症市場佔有率(2007∼2015年)

• 各級藥物:骨質疏鬆症市場佔有率與預測
• 各藥物市場佔有率:骨質疏鬆症市場佔有率與預測
• 各國(美國，歐洲，日本，中國，印度，韓國):骨質疏鬆症市場佔有率與預測

第4章 各國骨質疏鬆症市場及預測(2008∼2015年)

• 美國市場及預測
• 歐洲市場及預測
• 日本市場及預測
• 中國市場及預測
• 韓國市場及預測
• 印度市場及預測

第5章 各類藥物市場與預測(2004∼2014年)

• 雙磷酸鹽
• 選擇性雌激素受體調節劑（SERM)
• 副甲狀腺素
• 降鈣素

第6章 藥物市場分析與預測(2004∼2015年)

• 雙磷酸鹽市場及預測
  • Fosamax
  • Bonviva/Boniva
  • Reclast/Aclasta
  • Actone
• SERM藥物市場及預測
  • Evista
  • Viviant/ Conbriza
• 副甲狀腺素市場及預測
  • Forteo
• 抑鈣素藥物市場及預測
  • Miacalcin
• Prolia

第7章 骨質疏鬆症市場分析的開發平台分析

• Odanacatib (MK 0822)
• Aprela (Bazedoxifene)

第8章 骨質疏鬆症治療藥物市場專利契約(2008∼2009年)

• 主要企業分析
• Eli Lilly
• Roche
• Amgen
• Merck
• Novartis
  • 收益
  • 優勢
  • 弱點

圖表

目錄

Abstract

Market Overview

Osteoporosis is often called the “silent disease” because bone loss occurs without symptoms. It is characterized by low bone mass and micro-architectural deterioration of bone tissue, leading to bone fragility and a consequent increase in risk of fracture. Global osteoporosis market is expected to reach 16 Billion by 2015. This significant growth is primarily attributed to strong treatment options currently available in the market as well as strong pipeline products. The increase in the prevalence of osteoporosis among the female population is the principal driver of the osteoporosis market and will continue to be in the future.

Fosamax was the undisputed leading product in the history of global osteoporosis drug market till 2007. It has a market share of nearly 37% in 2007 but, declined to 5% by 2015 due to patent expiry and competition from cheaper generics. Boniva and Evista were leading the osteoporosis market till 2010 but the dynamics of osteoporosis market is expected to change by 2011 as Prolia is going to be introduced in the market. It is predicted that Prolia will lead the market with nearly 45% share by 2015.

The osteoporosis market offers multiple opportunities for current and future market players. In addition to increasing awareness, diagnosis and treatment, there is the need to develop new drugs that promote bone building. While the market awaits new growth, driven by the launch of several promising pipeline drugs, including Amgen' s Prolia (denosumab), companies are looking for innovative ways to maximize revenues from their products nearing the end of their lifecycles.

Report Details

“Global Osteoporosis Market & Drugs Analysis 2010 - 2015” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering:

• Global Osteoporosis Market (2009 to 2015)
• Four Osteoporosis Drug Class (Bisphosphonate, SERM, PTH and Calcitonin) market and market share data of (2006 to 2014)
• Top Nine Osteoporosis Drug Brand (Fosamax, Actonel, Reclast, Boniva, Evista, Forteo, Viviant/Conbriza, Miacalcin, Prolia) sales and market share data of 2007 to 2015
• Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market share data of (2009 to 2015)
• Six Countries (USA, European Union, Japan, China, India, Korea) Osteoporosis market data of (2005 to 2015)
• Pipeline Developmental Agents (Odanacatib, Aprela) Future Trends
• Key Companies (Eli Lilly, Roche, Amgen, Merck & Novartis) Analysis - Revenue in Osteoporosis Market (2007 to 2010), Strength & Weakness in Osteoporosis Market

Research Highlights

• Global Osteoporosis drug market is expected to reach the figure of US$ 16 Billion by 2015
• United States Osteoporosis drug market was nearly US$ 5 Billion in 2010
• United States & China together is expected to control 61% market share in osteoporosis drug market by 2015
• Although SERM is increasing its market share year on year but Bisphosphonates will continue to dominate the osteoporosis drug class segment with 56% in 2014
• Prolia will lead the Osteoporosis drug market with 45% share by 2015

Data Sources

Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, News websites, Government Agencies, Magazines, Newspapers, Trade associations, Books, Industry Portals, Industry Associations and access to more than 100 paid databases.

Table of Contents

1. Executive Summary

2. Global Osteoporosis Market

3. Global Osteoporosis Market Share (2007 - 2015)

• 3.1. By Drug Class - Osteoporosis Market Share & Forecast
• 3.2. By Drug Market Share - Osteoporosis Market Share & Forecast
• 3.3. By Country (USA, European Union, Japan, China, India, Korea) - Osteoporosis Drug Market Share & Forecast

4. By Country - Osteoporosis Market & Forecast (2008 - 2015)

• 4.1. United States Osteoporosis Market & Forecast
• 4.2. European Union Osteoporosis Market & Forecast
• 4.3. Japan Osteoporosis Market & Forecast
• 4.4. China Osteoporosis Market & Forecast
• 4.5. Korea Osteoporosis Market & Forecast
• 4.6. India Osteoporosis Market & Forecast

5. Osteoporosis Drugs Classes Market & Forecast (2004 - 2014)

• 5.1. Global Bisphosphonate Market & Forecast
• 5.2. Global Selective Estrogen Receptor Modulators (SERM) Market & Forecast
• 5.3. Global Parathyroid Hormone (PTH) Market & Forecast
• 5.4. Global Calcitonin Market & Forecast

6. Osteoporosis Drugs Market Analysis & Forecast (2004 - 2015)

• 6.1. Bisphosphonate Drugs Market & Forecast
  • 6.1.1. Fosamax (Alendronate)
  • 6.1.2. Bonviva/Boniva (Ibandronic Acid)
  • 6.1.3. Reclast/Aclasta
  • 6.1.4. Actonel (Risedronate)
• 6.2. SERMs Drugs Market & Forecast
  • 6.2.1. Evista (Raloxifene)
  • 6.2.2. Viviant/ Conbriza (Bazedoxifene)
• 6.3. Parathyroid Hormone Drugs Market & Forecast
  • 6.3.1. Forteo
• 6.4. Calcitonin Drugs Market & Forecast
  • 6.4.1. Miacalcin
• 6.5. Prolia (Denosumab)

7. Pipeline Drugs in Osteoporosis Market Analysis

• 7.1. Odanacatib (MK 0822)
• 7.2. Aprela (Bazedoxifene)

8. Licensing Deals in Osteoporosis Drug Market (2008 - 2009)

9. Key Companies Analysis

• 9.1. Eli Lilly
  • 9.1.1. Eli Lilly Revenue in Osteoporosis Segment
  • 9.1.2. Strength
  • 9.1.3. Weaknesses
• 9.2. Roche
  • 9.2.1. Roche Revenue in Osteoporosis Segment
  • 9.2.2. Strength
  • 9.2.3. Weaknesses
• 9.3. Amgen
  • 9.3.1. Strength
  • 9.3.2. Weaknesses
• 9.4. Merck
  • 9.4.1. Merck Revenue in Osteoporosis Segment
  • 9.4.2. Strength
  • 9.4.3. Weaknesses
• 9.5. Novartis
  • 9.5.1. Novartis Revenue in Osteoporosis Segment
  • 9.5.2. Strength
  • 9.5.3. Weaknesses

List of Figures:

• Figure 2 1: Global - Osteoporosis Market (Million US$), 2009 - 2010
• Figure 2 2: Global - Forecast for Osteoporosis Market (Million US$), 2011 - 2015
• Figure 3 1: Global - Osteoporosis Drug Class Market Share (Percent), 2006 - 2010
• Figure 3 2: Global - Forecast for Osteoporosis Drug Class Market Share (Percent), 2011 - 2014
• Figure 3 3: Global - Osteoporosis Drug Market Share (Percent), 2007 - 2010
• Figure 3 4: Global - Forecast for Osteoporosis Drug Market Share (Percent), 2011 - 2015
• Figure 3 5: Global - Osteoporosis Drug Market Share of (USA, European Union, Japan, China, India, Korea) (Percent), 2009 - 2010
• Figure 3 6: Global - Forecast for Osteoporosis Drug Market Share of (USA, European Union, Japan, China, India, Korea) (Percent), 2011 - 2015
• Figure 4 1: United States - Osteoporosis Market (Million US$), 2008 - 2010
• Figure 4 2: United States - Forecast for Osteoporosis Market (Million US$), 2011 - 2021
• Figure 4 3: European Union - Osteoporosis Market (Million US$), 2009 - 2010
• Figure 4 4: European Union - Forecast for Osteoporosis Market (Million US$), 2011 - 2015
• Figure 4 5: Japan - Osteoporosis Market (Billion Yen), 2001 - 2010
• Figure 4 6: Japan - Forecast for Osteoporosis Market (Billion Yen), 2011 - 2015
• Figure 4 7: China - Osteoporosis Market (Million US$), 2004 - 2010
• Figure 4 8: China - Forecast for Osteoporosis Market (Million US$), 2011 - 2015
• Figure 4 9: Korea - Osteoporosis Market (Million US$), 2001 - 2010
• Figure 4 10: Korea - Forecast for Osteoporosis Market (Million US$), 2011 - 2015
• Figure 4 11: India - Osteoporosis Market (Million INR), 2007 - 2010
• Figure 4 12: India - Forecast for Osteoporosis Market (Million INR), 2011 - 2015
• Figure 5 1: Global - Bisphosphonate Market (Million US$), 2004 - 2010
• Figure 5 2: Global - Forecast for Bisphosphonate Market (Million US$), 2011 - 2014
• Figure 5 3: Global - SERM Market (Million US$), 2004 - 2010
• Figure 5 4: Global - Forecast for SERM Market (Million US$), 2011 - 2014
• Figure 5 5: Global - PTH Market (Million US$), 2004 - 2010
• Figure 5 6: Global - Forecast for PTH Market (Million US$), 2011 - 2014
• Figure 5 7: Global - Calcitonin Market (Billion US$), 2004 - 2010
• Figure 5 8: Global - Forecast for Calcitonin Market (Billion US$), 2004 - 2010
• Figure 6 1: Global - Fosamax Drug Sales (Million US$), 2003 - 2010
• Figure 6 2: Global - Forecast for Fosamax Drug Sales (Million US$), 2011 - 2015
• Figure 6 3: Global - Boniva Drug Sales (Million US$), 2005 - 2010
• Figure 6 4: Global - Forecast for Boniva Drug Sales (Million US$), 2011 - 2015
• Figure 6 5: Global - Reclast/Aclasta Drug Sales (Million US$), 2007 - 2010
• Figure 6 6: Global - Forecast for Reclast/Aclasta Drug Sales (Million US$), 2011 - 2015
• Figure 6 7: Global - Actonel Drug Sales (Million US$), 2004 - 2010
• Figure 6 8: Global - Forecast for Actonel Drug Sales (Million US$), 2011 - 2013
• Figure 6 10: Global - Evista Drug Sales (Million US$), 2001 - 2010
• Figure 6 11: Global - Forecast for Evista Drug Sales (Million US$), 2011 - 2015
• Figure 6 12: Global - Viviant/Conbriza Drug Sales (Million US$), 2010 - 2015
• Figure 6 13: Global - Forteo Drug Sales (Million US$), 2003 - 2010
• Figure 6 14: Global - Forecast for Forteo Drug Sales (Million US$), 2011 - 2015
• Figure 6 15: Global - Miacalcin Drug Sales (Million US$), 2004 - 2010
• Figure 6 16: Global - Forecast for Miacalcin Drug Sales (Million US$), 2011 - 2015
• Figure 6 17: Global - Forecast for Prolia Drug (Million US$), 2010 - 2016
• Figure 7 1: Global - Forecast for Odanacatib Drug (Million US$), 2012 - 2015
• Figure 7 2: Global - Forecast for Aprela Drug Sales (Million US$), 2011 - 2015
• Figure 9 1: Eli Lilly - Osteoporosis Drug Revenue (Million US$), 2007 - 2010
• Figure 9 2: Roche - Osteoporosis Drug Revenue (Million US$), 2007 - 2010
• Figure 9 3: Merck - Osteoporosis Drug Revenue (Million US$), 2007 - 2010
• Figure 9 4: Novartis - Osteoporosis Drug Revenue (Million US$), 2007 - 2010

List of Tables:

• Table 6 1: Actonel (Eisai, P&G and Sanofi-Aventis) - Sales (Million US$), 2004 - 2013
• Table 6 2: Benet (Risedronate) - Sales (Million US$), 2004 - 2013
• Table 9 1: Osteoporosis - Drugs Cost Comparison (US$) in 1 Year

相關商品

骨頭疾病治療相關市場調查報告書

全球及中國的骨質疏鬆症治療藥物市場:市場規模·市場趨勢·市場預測(2010-2015年)
Osteoporosis Drug Market- Global And China Market Analysis, Size, Trends And Forecast (2010-2015)
價格 : US $ 2395
出版日期 : 2012年01月

中國的骨質疏鬆症市場分析與預測(2007年∼2015年)
China Osteoporosis Market Analysis and Forecast, 2007 - 2015
價格 : US $ 1500
出版日期 : 2012年01月

全球肌肉骨骼疾病治療藥物的市場(到2017年為止)
Musculoskeletal Disorders Therapeutics Market to 2017 - Osteoarthritis Market to Decline with Patent Expiry of Celebrex in 2014
價格 : US $ 3500
出版日期 : 2012年01月

Renub Research發行的製藥相關市場調查報告書

泰國的醫療旅遊:遊客數及市場規模的預測(∼2015年)

Thailand Medical Tourist Arrivals, Medical Tourism Market & Forecast to 2015

價格 : US $ 800

出版日期 : 2012年04月

C型肝炎(HCV)市場預測及藥物開發平台分析:∼2016年

Hepatitis C (HCV) Market Forecast & Drugs Pipeline Analysis to 2016

價格 : US $ 975

出版日期 : 2012年01月

全球流感疫苗市場:市場機會·課題·市場預測

Influenza Vaccine Market Opportunities and Challenges: Worldwide Forecast

價格 : US $ 1100

出版日期 : 2012年01月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!